- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03024359
Monounsaturated Fatty Acids and Brown/Beige Adipose Tissue in Humans
Effect of Monounsaturated Fatty Acids Consumption in Brown/Beige Adipose Tissue Activity in Human Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HYPOTHESIS The effects of fatty acids consumption on brown / beige adipose tissue have not yet been explored in humans. However, studies that evaluated the effects of saturated fatty acid replacement by monounsaturated fatty acids (MUFAs) or polyunsaturated fatty acids (PUFAs) on animal and human models have observed an improvement in cardiovascular risk factors, such as reduction of subclinical inflammation, improvement of lipid profile and increase in insulin sensitivity. The mechanisms by which these fatty acids act in the improvement of risk factors have not been completely clarified and it is possible that there is an association between the reduction of cardiovascular risk factors and the activation of brown / beige adipose tissue.
Our hypothesis is that consuming extra virgin olive oil in high amounts for one month will promote increased brown adipose tissue (BAT) activity of the participants and improve the cardiovascular risk profile, as assessed by inflammatory markers. It is possible that the response of lean and obese subjects to dietary intervention is different and that the behavior of BAT is not equal in both groups.
OBJECTIVE To evaluate the impact of the consumption of large amounts of extra virgin olive oil (source of monounsaturated fatty acids) on the activity of brown / beige adipose tissue in lean and obese humans.
2.1 Specific objectives • To investigate the activity of brown and beige adipose tissue by FDG PET / RMI, before and after four weeks of intervention with high amount of extra virgin olive oil; • To evaluate the expression of BAT activity markers: uncoupling protein 1 (UCP-1), PR domain containing 16 (PRDM16), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), iodothyronine deiodinase 2 (Dio2) in mononuclear cells in the whole sample;
- To evaluate levels of fatty acids in the blood by gas chromatography, before and after the intervention to evaluate changes in fatty acid intake;
- To evaluate concentrations of pro and anti-inflammatory cytokines in the blood before and after 4 weeks of intervention: tumor necrosis factor alpha (TNF-α), interleukin 1-beta (IL1β), Monocyte Chemoattractant Protein-1 (MCP-1), interleukin-6 and interleukin-10);
- To evaluate the effects of interventions on metabolic markers before and after the intervention: leptin, insulin, glucose, total cholesterol and fractions, triglycerides;
- To evaluate the effects of the intervention on anthropometry (weight, abdominal circumference) and on the body composition evaluated by Dual-energy X-ray absorptiometry (DXA);
- To evaluate the effects of dietary interventions on brain activity (by PET/MRi) in a subsample of 15 individuals.
MATERIALS AND METHODS This will be an open clinical trial lasting for four weeks. The study consists of two data collections before and after a 4-week dietary intervention in which participants will be required to consume extra-virgin olive oil provided by the researchers.
The collection of socio demographic, dietary and physical activity data, as well as the PET / MRI and the blood collections of 50 participants will be carried out at the Nuclear Medicine Center of the Medical School of the University of São Paulo. Bone densitometry (DXA) will be performed at the School of Public Health of the University of São Paulo.
Selection of participants:
The estimated number of individuals with a detectable brown adipose tissue (50) is 50%, with the proportion of individuals with detectable brown adipose tissue. It will include 15 obese individuals (degree I obesity) and 35 control subjects (normal weight individuals). Participants will be selected through print and electronic media.
• Inclusion criteria For the group with obesity: Both genders, age between 25 and 40 years, BMI ≥ 30 and <35 kg / m2.
For the normal weight group (control): Both genders, age between 25 and 40 years, BMI <25 kg / m2.
Exclusion Criteria
1) Residing outside of São Paulo / Campinas; 2) pregnant women; 3) patients with severe or non-stabilized neurological or psychiatric problems; 4) use of anti-obesity or lipid-lowering medication; 5) use of adrenergic or benzodiazepine drugs; 6) individuals with neoplasms, transmissible and rheumatic diseases, hepatic or renal insufficiency, untreated thyroid dysfunction; Diabetes mellitus; 7) change of more than 5% of body weight in the last six months; 8) to be carrying out some kind of diet or modification in the usual dietary pattern; 9) have metal prostheses.
- Design This is an open clinical trial with a total duration of four weeks. Obese and controls participants will be enrolled into a dietary intervention for 4 weeks with extra virgin olive oil (MUFA rich). Extra-virgin olive oil (2 liters) is provided to participants and the researchers adivice the participants to use the oil in all preparations during the four weeks.
Before and after each intervention period the following data will be collected:
- Food consumption: 24-hour recall (before and after dietary intervention) and 3-day food diary;
- Physical activity data: International Physical Activity Questionnaire (IPAQ);
- Evaluation of brown / beige adipose tissue volume and activity:
Positron emission tomography with fluoride-18-labeled fluorodeoxyglucose (18F-FDG) in combination with magnetic resonance (PET / MRi).
For the FDG PET / RMI the participants will be allocated in a room with controlled temperature (19 degrees), with light clothes and a cooling vest for 2 hours.
- Body composition assessment: Weight (digital scale) and height (fixed stadiometer);; abdominal circumference; body composition: by Dual-energy X-ray absorptiometry (DXA);
- Biochemical dosages: plasma glucose, triglycerides, total cholesterol and HDL-c will be determined routinely and inflammatory markers will be determined by enzyme-linked immunosorbent assay (ELISA);
- Expression of UCP-1, PGC-1α, PRDM16 and Dio2 will be performed by Real-Time Polymerase chain reaction (RT-PCR);
- Composition of fatty acids in plasma will be determined by gas chromatography;
- Brain activity: will be performed in a subsample of 15 individuals using 18F-FDG PET/MRi.
• Statistical analysis Data will be expressed as mean and standard deviation and the variables compared by Student's t-test or ANOVA for repeated measures.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13083-887
- Faculdade de Ciências Médicas Unicamp
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Gender: Both Age: 25 to 40 years
Body mass index (BMI):
Normal body weight group: BMI lower than 25 kg/m2 Obese group: BMI between 30 and 35 kg/m2
Exclusion Criteria:
- Living outside of São Paulo;
- pregnant women;
- patients with severe or non-stabilized neurological or psychiatric problems;
- use of anti-obesity or lipid-lowering medication;
- use of adrenergic or benzodiazepine drugs;
- individuals with neoplasms, transmissible and rheumatic diseases, hepatic or renal insufficiency, untreated thyroid dysfunction; Diabetes mellitus;
- individuals that changed more than 5% of body weight in the last six months; 8) to be carrying out some kind of diet or modification in the usual dietary pattern; 9) having metal prostheses.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: obese individuals
Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil.
Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
|
2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
|
|
Active Comparator: normal weight individuals
Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil.
Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
|
2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brown adipose tissue activity measured by increase in mean standardized disposal value (SUV)
Time Frame: Four weeks
|
We will investigate whether 4 weeks of olive oil consumption can increase the activity of brown adipose tissue measured by mean standardized disposal value (volume) using magnetic resonance imaging
|
Four weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hypothalamic inflammation
Time Frame: Four weeks
|
To see whether the consumption of 4 weeks of olive oil is able to reduce hypothalamic inflammation in lean and obese individuals as measured by functional resonance imaging
|
Four weeks
|
|
Lipid profile
Time Frame: Four weeks
|
To see whether the consumption of 4 weeks of olive oil is able to reduce LDL and total cholesterol, as well as triglycerides concentrations
|
Four weeks
|
|
Inflammatory markers
Time Frame: Four weeks
|
To see whether the consumption of 4 weeks of olive oil is able to reduce pro-inflammatory markers (TNF-alpha, interleukin-1beta) and increase interleukin-10
|
Four weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Milena Monfort-Pires, PhD, University of Campinas
- Study Director: Licio A Velloso, Professor, University of Campinas
Publications and helpful links
General Publications
- van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009 Apr 9;360(15):1500-8. doi: 10.1056/NEJMoa0808718. Erratum In: N Engl J Med. 2009 Apr 30;360(18):1917.
- Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, Schrauwen P, van Marken Lichtenbelt WD. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2012 Jul;97(7):E1229-33. doi: 10.1210/jc.2012-1289. Epub 2012 Apr 24.
- Chondronikola M, Annamalai P, Chao T, Porter C, Saraf MK, Cesani F, Sidossis LS. A percutaneous needle biopsy technique for sampling the supraclavicular brown adipose tissue depot of humans. Int J Obes (Lond). 2015 Oct;39(10):1561-4. doi: 10.1038/ijo.2015.76. Epub 2015 Apr 29.
- Monfort-Pires M, U-Din M, Nogueira GA, de Almeida-Faria J, Sidarta-Oliveira D, Sant'Ana MR, De Lima-Junior JC, Cintra DE, de Souza HP, Ferreira SRG, Sapienza MT, Virtanen KA, Velloso LA. Short Dietary Intervention with Olive Oil Increases Brown Adipose Tissue Activity in Lean but not Overweight Subjects. J Clin Endocrinol Metab. 2021 Jan 23;106(2):472-484. doi: 10.1210/clinem/dgaa824.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CAAE: 60698716.1.0000.5404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obese
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustCompleted
-
National Science and Technology Council, TaiwanMinistry of Science and Technology, Taiwan; Fondation FondaMental; Fondation...Recruiting
-
Ain Shams UniversityNot yet recruitingBleeding | Obese Patients | Obese Patients With Bariatric SurgerySaudi Arabia
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Aphaia Pharma US LLCRecruitingObese Patients (BMI ≥ 30 kg/m²) | Obese With ComorbiditiesGeorgia
-
University Hospital, GhentCompleted
-
Yongxin ZhouNot yet recruiting
-
Universitas PadjadjaranCompleted
-
University of AvignonInstitut Saint PierreRecruitingDiet Modification | Exercise | Dietary Supplement | Obese AdolescentsFrance
Clinical Trials on Extra virgin olive oil
-
Old Dominion UniversityNot yet recruitingHeart Failure With Reduced Ejection Fraction (HFrEF)United States
-
University of California, DavisCompletedCardiovascular Diseases | Platelet Aggregation | Nutritional and Metabolic DiseaseUnited States
-
Efforia, IncRecruiting
-
Greek Alzheimer's Association and Related DisordersUnknownMild Cognitive ImpairmentGreece
-
Ankara City Hospital BilkentHacettepe UniversityCompleted
-
Ralph HamillCompletedCardiovascular DiseasesUnited States
-
Javad NasrollahzadehShahid Beheshti University of Medical SciencesCompletedCardiovascular Risk FactorIran, Islamic Republic of
-
University of BarcelonaHospital Clinic of Barcelona; Institut d'Investigacions Biomèdiques August...Completed
-
Griffin HospitalCompletedType 2 DiabetesUnited States
-
Universidad de GranadaUniversity of Jaén; NOTALIV cosmética naturalCompletedIleostomy - Stoma | Peristomal Skin Complication | Colostomy StomaSpain